JP2008545793A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008545793A5 JP2008545793A5 JP2008515915A JP2008515915A JP2008545793A5 JP 2008545793 A5 JP2008545793 A5 JP 2008545793A5 JP 2008515915 A JP2008515915 A JP 2008515915A JP 2008515915 A JP2008515915 A JP 2008515915A JP 2008545793 A5 JP2008545793 A5 JP 2008545793A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen atom
- aralkyl
- alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 124
- 125000000217 alkyl group Chemical group 0.000 claims 123
- 125000003710 aryl alkyl group Chemical group 0.000 claims 112
- 125000003118 aryl group Chemical group 0.000 claims 109
- 150000001875 compounds Chemical class 0.000 claims 43
- 125000005843 halogen group Chemical group 0.000 claims 40
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 36
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 34
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 claims 34
- 239000000126 substance Substances 0.000 claims 34
- 125000003545 alkoxy group Chemical group 0.000 claims 33
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 33
- 125000004104 aryloxy group Chemical group 0.000 claims 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 33
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 31
- 125000004442 acylamino group Chemical group 0.000 claims 27
- 125000004423 acyloxy group Chemical group 0.000 claims 27
- -1 aralkylene group Chemical group 0.000 claims 27
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 27
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims 27
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 27
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 24
- 150000001408 amides Chemical class 0.000 claims 24
- 150000002148 esters Chemical class 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 24
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 12
- 125000002947 alkylene group Chemical group 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 125000002252 acyl group Chemical group 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 9
- 102000015534 trkB Receptor Human genes 0.000 claims 8
- 108010064880 trkB Receptor Proteins 0.000 claims 8
- 125000000732 arylene group Chemical group 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000005649 substituted arylene group Chemical group 0.000 claims 6
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 5
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 5
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 230000001105 regulatory effect Effects 0.000 claims 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000002569 neuron Anatomy 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 101150056950 Ntrk2 gene Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 0 *C(C1*)C(*C(*=C(C*I*)C=*)=O)*C1I* Chemical compound *C(C1*)C(*C(*=C(C*I*)C=*)=O)*C1I* 0.000 description 12
- CXIGIXHNCUFRDV-UHFFFAOYSA-N CCCN(CCO)c1ccc(C(c(cc2)ccc2N(CCO)CCO)c(cc2)ccc2Cl)cc1 Chemical compound CCCN(CCO)c1ccc(C(c(cc2)ccc2N(CCO)CCO)c(cc2)ccc2Cl)cc1 CXIGIXHNCUFRDV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68876705P | 2005-06-08 | 2005-06-08 | |
| US60/688,767 | 2005-06-08 | ||
| PCT/US2006/022268 WO2006133353A2 (en) | 2005-06-08 | 2006-06-08 | Methods of facilitating neural cell survival using non-peptide and peptide bdnf neurotrophin mimetics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008545793A JP2008545793A (ja) | 2008-12-18 |
| JP2008545793A5 true JP2008545793A5 (enExample) | 2009-07-30 |
| JP5461009B2 JP5461009B2 (ja) | 2014-04-02 |
Family
ID=37499118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008515915A Active JP5461009B2 (ja) | 2005-06-08 | 2006-06-08 | 非ペプチド及びペプチドｂｄｎｆニューロトロフィン類似体を用いた神経細胞生存促進法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8686045B2 (enExample) |
| EP (3) | EP1893192A4 (enExample) |
| JP (1) | JP5461009B2 (enExample) |
| ES (1) | ES2569881T3 (enExample) |
| WO (1) | WO2006133353A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7785829B2 (en) | 2003-03-19 | 2010-08-31 | Biogen Idec Ma, Inc. | Nogo receptor binding protein |
| BRPI0512500A (pt) | 2004-06-24 | 2008-03-11 | Biogen Idec Inc | tratamento ou condições envolvendo desmielinação |
| US20110230479A1 (en) * | 2005-04-15 | 2011-09-22 | Longo Frank M | Neurotrophin mimetics and uses thereof |
| EP2594318B1 (en) * | 2005-04-15 | 2020-06-10 | University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
| EP1893192A4 (en) | 2005-06-08 | 2010-03-31 | Univ North Carolina | METHOD FOR ENABLING SURVIVAL OF NERVE CELLS BASED ON NON-PEPTIDIC AND PEPTIDIC BDNF NEUROTROPHINE MIMETICS |
| PL1904104T3 (pl) | 2005-07-08 | 2014-02-28 | Biogen Ma Inc | Przeciwciała SP35 i ich zastosowania |
| WO2008078179A1 (en) * | 2006-12-20 | 2008-07-03 | Rinat Neuroscience Corporation | Trkb agonists for treating autoimmune disorders |
| EP2205071B1 (en) * | 2007-10-11 | 2015-07-22 | Biogen MA Inc. | Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma |
| WO2009061500A1 (en) * | 2007-11-08 | 2009-05-14 | Biogen Idec Ma Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
| WO2009086202A2 (en) * | 2007-12-19 | 2009-07-09 | Afraxis, Inc. | Methods for treating neuropsychiatric conditions |
| US20100317715A1 (en) * | 2007-12-21 | 2010-12-16 | Vollrath Benedikt | Methods for treating neuropsychiatric conditions |
| CA2997870A1 (en) | 2008-07-09 | 2010-01-14 | Biogen Ma Inc. | Compositions comprising antibodies to lingo or fragments thereof |
| US9040538B2 (en) | 2009-05-21 | 2015-05-26 | Universite Laval | Pyrimidines as novel therapeutic agents |
| KR101138048B1 (ko) | 2009-11-06 | 2012-04-23 | 성균관대학교산학협력단 | Ｂｄｎｆ의 발현을 증가시키는 신규 펩타이드 및 이를 포함하는 알츠하이머병 또는 파킨슨병의 예방 및 치료용 약학 조성물 |
| EP2498782B1 (en) | 2009-11-12 | 2019-01-09 | Pharmatrophix Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
| US8901129B2 (en) | 2009-12-11 | 2014-12-02 | Genecode As | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators |
| US20120004310A1 (en) * | 2010-05-28 | 2012-01-05 | Longo Frank M | Non-peptide bdnf neurotrophin mimetics |
| EA030716B1 (ru) | 2012-05-14 | 2018-09-28 | Байоджен Ма Инк. | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны |
| JP6120311B2 (ja) * | 2013-02-12 | 2017-04-26 | 学校法人銀杏学園 | ポリフェノール化合物 |
| BR112015022836A2 (pt) * | 2013-03-15 | 2017-07-18 | Pharmatrophix Inc | miméticos de neurotrofina bdnf não peptídicos |
| AU2014227623B2 (en) * | 2013-03-15 | 2018-08-16 | Pharmatrophix, Inc. | Non-peptide BDNF Neurotrophin mimetics |
| CA2909270A1 (en) | 2013-04-12 | 2014-10-16 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of hcv |
| CN118286245A (zh) | 2014-12-26 | 2024-07-05 | 埃莫里大学 | N4-羟基胞苷和衍生物及与其相关的抗病毒用途 |
| JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用 |
| EP3303588A4 (en) * | 2015-05-29 | 2019-01-23 | The Board of Trustees of The Leland Stanford Junior University | NUCLEOSIDE AGENTS TO REDUCE THE HARMFUL ACTIVITY OF GENES WITH EXTENDED NUCLEOTIDE REPEAT |
| JP6923509B2 (ja) * | 2015-07-28 | 2021-08-18 | オトノミ—，インク． | 切断型のｔｒｋｂおよびｔｒｋｃのアンタゴニストを使用する処置 |
| WO2017123826A1 (en) | 2016-01-14 | 2017-07-20 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| RS66222B1 (sr) | 2017-12-07 | 2024-12-31 | Univ Emory | N4-hidroksicitidin i derivati i antivirusne upotrebe povezane sa njim |
| EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2021242923A1 (en) | 2020-05-27 | 2021-12-02 | Axial Therapeutics, Inc. | Tlr2 modulator compounds, pharmaceutical compositions and uses thereof |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| AU2022380979A1 (en) | 2021-11-02 | 2024-06-06 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
| US12116382B2 (en) | 2022-11-28 | 2024-10-15 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine analogs |
| CN116554123A (zh) * | 2023-04-27 | 2023-08-08 | 山东大学 | 六种噻唑酰腙类化合物在抗肿瘤药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2109262A5 (enExample) | 1970-10-08 | 1972-05-26 | Inst Francais Du Petrole | |
| US3953416A (en) * | 1971-12-20 | 1976-04-27 | Karl Folkers | Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same |
| JPS5025442B2 (enExample) | 1972-03-14 | 1975-08-23 | ||
| DE2343037A1 (de) * | 1973-08-25 | 1975-03-06 | Hoechst Ag | Arzneimittel mit antidepressiver wirkung |
| HU185535B (en) * | 1982-05-25 | 1985-02-28 | Mta Koezponti Hivatala | Process for preparing new gonadoliberin derivatives |
| US5321029A (en) * | 1988-11-14 | 1994-06-14 | Beecham-Wuelfing Gmbh & Co.K.G. | Xanthines |
| GB9402331D0 (en) * | 1994-02-07 | 1994-03-30 | Univ Mcgill | Nerve growth factor structural analogs and their uses |
| AU4117396A (en) | 1994-11-29 | 1996-06-19 | Novartis Ag | Morpholinoethylamide derivatives |
| US5958875A (en) * | 1996-03-29 | 1999-09-28 | The Regents Of The University Of California | Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity |
| EP1008656A4 (en) | 1996-06-13 | 2000-09-20 | Itoham Foods Inc | METHOD FOR PRODUCING LH-RH DERIVATIVES |
| WO2000006137A2 (en) | 1998-07-30 | 2000-02-10 | Abbott Laboratories | Glucocorticoid-selective anti-inflammatory agents |
| US6780580B2 (en) * | 1999-03-17 | 2004-08-24 | The University Of North Carolina At Chapel Hill | Method of screening candidate compounds for susceptibility to biliary excretion |
| US6583148B1 (en) * | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
| EP1265605B1 (en) * | 2000-01-18 | 2006-09-27 | McGILL UNIVERSITY | Pharmaceutical compositions comprising beta-turn peptidomimetic cyclic compounds |
| AU2002228316A1 (en) * | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| JP2006503069A (ja) | 2002-09-25 | 2006-01-26 | ジョージア テック リサーチ コーポレイション | 慢性神経疾患におけるケトアミド阻害剤 |
| EP2594318B1 (en) | 2005-04-15 | 2020-06-10 | University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
| EP1893192A4 (en) | 2005-06-08 | 2010-03-31 | Univ North Carolina | METHOD FOR ENABLING SURVIVAL OF NERVE CELLS BASED ON NON-PEPTIDIC AND PEPTIDIC BDNF NEUROTROPHINE MIMETICS |
-
2006
- 2006-06-08 EP EP06784665A patent/EP1893192A4/en not_active Withdrawn
- 2006-06-08 ES ES12169982.1T patent/ES2569881T3/es active Active
- 2006-06-08 EP EP12169982.1A patent/EP2581440B1/en not_active Not-in-force
- 2006-06-08 WO PCT/US2006/022268 patent/WO2006133353A2/en not_active Ceased
- 2006-06-08 EP EP12169984.7A patent/EP2526942B1/en active Active
- 2006-06-08 JP JP2008515915A patent/JP5461009B2/ja active Active
- 2006-06-08 US US11/449,381 patent/US8686045B2/en active Active
-
2014
- 2014-01-27 US US14/165,090 patent/US9604907B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008545793A5 (enExample) | ||
| JP2009504748A5 (enExample) | ||
| TWI316942B (en) | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents | |
| JP5596680B2 (ja) | 経口抗がん製剤 | |
| JP2005537268A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| KR20170086710A (ko) | 피로의 치료 또는 예방 방법 | |
| JP2010538001A5 (enExample) | ||
| JP2006507220A5 (enExample) | ||
| JP2003509349A5 (enExample) | ||
| JP2007530577A5 (enExample) | ||
| JP2013513588A5 (enExample) | ||
| CN1071913A (zh) | 反胺苯环醇n-氧化物及其对映异构件体和组合物，以及它们的应用 | |
| JP2017519775A5 (enExample) | ||
| JP2007502832A5 (enExample) | ||
| JP2009541493A5 (enExample) | ||
| WO2008092072A3 (en) | Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof | |
| EP1986647A2 (en) | 4-acylaminopyridine derivative mediated neurogenesis | |
| JP2008536844A5 (enExample) | ||
| ATE453617T1 (de) | Substituierte n-arylbenzamide und verwandte verbindungen zur behandlung von amyloidkrankheiten und synukleinopathien | |
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| JP2025163212A (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| JP2006503095A5 (enExample) | ||
| CA3046458A1 (en) | Parenteral liquid preparation comprising carbamate compound |